74 related articles for article (PubMed ID: 21136699)
21. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
22. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
23. Prostate specific antigen in benign prostatic hyperplasia: purification and characterization.
Chen Z; Chen H; Stamey TA
J Urol; 1997 Jun; 157(6):2166-70. PubMed ID: 9146608
[TBL] [Abstract][Full Text] [Related]
24. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling.
Luo J; Duggan DJ; Chen Y; Sauvageot J; Ewing CM; Bittner ML; Trent JM; Isaacs WB
Cancer Res; 2001 Jun; 61(12):4683-8. PubMed ID: 11406537
[TBL] [Abstract][Full Text] [Related]
25. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
26. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
Soulitzis N; Karyotis I; Delakas D; Spandidos DA
Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871
[TBL] [Abstract][Full Text] [Related]
27. Autoantibodies to prostate specific antigen in patients with benign prostatic hyperplasia.
Zisman A; Zisman E; Lindner A; Velikanov S; Siegel YI; Mozes E
J Urol; 1995 Sep; 154(3):1052-5. PubMed ID: 7543596
[TBL] [Abstract][Full Text] [Related]
28. Protein macroarray profiling of serum autoantibodies in pseudoexfoliation glaucoma.
Dervan EW; Chen H; Ho SL; Brummel N; Schmid J; Toomey D; Haralambova M; Gould E; Wallace DM; Prehn JH; O'Brien CJ; Murphy D
Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):2968-75. PubMed ID: 20107165
[TBL] [Abstract][Full Text] [Related]
29. Expression of the tumour antigen T21 is up-regulated in prostate cancer and is associated with tumour stage.
Miles AK; Rogers A; McCulloch T; Hodi Z; McArdle S; Bishop M; Rees RC
BJU Int; 2012 Mar; 109(5):796-805. PubMed ID: 21851547
[TBL] [Abstract][Full Text] [Related]
30. Serum keratinocyte growth factor measurement in patients with prostate cancer.
Mehta PB; Robson CN; Neal DE; Leung HY
J Urol; 2000 Dec; 164(6):2151-5. PubMed ID: 11061946
[TBL] [Abstract][Full Text] [Related]
31. Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism.
Wang Y; Shao C; Shi CH; Zhang L; Yue HH; Wang PF; Yang B; Zhang YT; Liu F; Qin WJ; Wang H; Shao GX
Asian J Androl; 2005 Dec; 7(4):375-80. PubMed ID: 16281084
[TBL] [Abstract][Full Text] [Related]
32. Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia?
Hall MC; Roehrborn CG; McConnell JD
Semin Urol Oncol; 1996 Aug; 14(3):122-33. PubMed ID: 8865473
[TBL] [Abstract][Full Text] [Related]
33. Characterization of autoantibody activities in sera anti-DNA antibody and circulating immune complexes from 12 systemic lupus erythematosus patients.
Adyel FZ; Hentati B; Boulila A; Hachicha J; Ternynck T; Avrameas S; Ayadi H
J Clin Lab Anal; 1996; 10(6):451-7. PubMed ID: 8951619
[TBL] [Abstract][Full Text] [Related]
34. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
Miyata Y; Sakai H; Hayashi T; Kanetake H
Prostate; 2003 Feb; 54(2):125-32. PubMed ID: 12497585
[TBL] [Abstract][Full Text] [Related]
35. Autoantibodies to Annexin XI-A and Other Autoantigens in the Diagnosis of Breast Cancer.
Fernández-Madrid F; Tang N; Alansari H; Granda JL; Tait L; Amirikia KC; Moroianu M; Wang X; Karvonen RL
Cancer Res; 2004 Aug; 64(15):5089-96. PubMed ID: 15289310
[TBL] [Abstract][Full Text] [Related]
36. A comparative study of serum protein-bound sialic acid in benign and malignant prostatic growth: possible role of oxidative stress in sialic acid homeostasis.
Goswami K; Nandeesha H; Koner BC; Nandakumar DN
Prostate Cancer Prostatic Dis; 2007; 10(4):356-9. PubMed ID: 17404581
[TBL] [Abstract][Full Text] [Related]
37. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
38. [Clinical significance of prostate specific antigen (PSA) and PSA density in the detection of T1a and T1b prostate cancer].
Meguro N; Maeda O; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T
Hinyokika Kiyo; 1998 Sep; 44(9):639-43. PubMed ID: 9805668
[TBL] [Abstract][Full Text] [Related]
39. Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features.
Aslan G; Irer B; Tuna B; Yorukoglu K; Saatcioglu F; Celebi I
Pathol Res Pract; 2006; 202(2):93-8. PubMed ID: 16413692
[TBL] [Abstract][Full Text] [Related]
40. Serum autoantibodies to alpha-fodrin are present in glaucoma patients from Germany and the United States.
Grus FH; Joachim SC; Bruns K; Lackner KJ; Pfeiffer N; Wax MB
Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):968-76. PubMed ID: 16505031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
